Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962825 | 1.00 | ELANE (0.37) | ELANEL3MBTL1PTGDR2RORCTNKS | |
| SCHEMBL965366 | 0.90 | L3MBTL1 (0.34) | ELANEL3MBTL1PTGDR2TBXAS1KDM5A | |
| SCHEMBL965368 | 0.90 | L3MBTL1 (0.34) | ELANEL3MBTL1PTGDR2TBXAS1KDM5A | |
| SCHEMBL964006 | 0.85 | ALDH1A1 (0.34) | L3MBTL1RORC | |
| SCHEMBL964008 | 0.85 | ALDH1A1 (0.34) | L3MBTL1RORC | |
| SCHEMBL963133 | 0.82 | L3MBTL1 (0.48) | ELANEL3MBTL1PTGDR2RORCTNKS | |
| SCHEMBL963132 | 0.82 | L3MBTL1 (0.48) | ELANEL3MBTL1PTGDR2RORCTNKS | |
| SCHEMBL963252 | 0.81 | ELANE (0.39) | ELANEL3MBTL1RORCTNKS | |
| SCHEMBL962302 | 0.81 | PARP1 (0.38) | L3MBTL1TBXAS1 | |
| SCHEMBL962301 | 0.81 | PARP1 (0.38) | L3MBTL1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | ELANE 3595/4885L3MBTL1 3858/4885PTGDR2 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.